Research progress of warfarin-associated vascular calcification and its possible therapy

Journal of Cardiovascular Pharmacology

Volumn 63, Issue 1, 2014, Pages 76-82

  Zhang, Yu Tao ^a   Tang, Ze Yao ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Matrix Gla protein; Therapy; Vascular calcification; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; BLOOD CLOTTING FACTOR; CYTOCHROME P450 2C9; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OSTEOCALCIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; VITAMIN K GROUP; WARFARIN; BIOLOGICAL MARKER;

BLEEDING DISORDER; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; DRUG MECHANISM; DRUG MONITORING; ENZYME ACTIVITY; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOIDY; HAPLOTYPE; HUMAN; LONG TERM CARE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEROLOGY; THROMBOEMBOLISM; BLOOD; CHEMICALLY INDUCED; VASCULAR CALCIFICATION;

ANTICOAGULANTS; BIOMARKERS; HUMANS; VASCULAR CALCIFICATION; WARFARIN;

EID: 84892913772     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000008     Document Type: Review

References (72)

1. Schori TR, Stungis GE. Long-Term warfarin treatment may induce arterial calcification in humans: Case report. Clin Invest Med. 2004;27:107-109
2. Villines TC, O'Malley PG, Feuerstein IM, et al. Does prolonged warfarin exposure potentiate coronary calcification in humans? Results of the warfarin and coronary calcification study. Calcif Tissue Int. 2009;85: 494-500
3. Palaniswamy C, Sekhri A, Aronow WS, et al. Association of warfarin use with valvular and vascular calcification: A review. Clin Cardiol. 2011;34:74-81
4. Jean G, Bresson E, Terrat JC, et al. Peripheral vascular calcification in long-haemodialysis patients: Associated factors and survival consequences. Nephrol Dial Transplant. 2009;24:948-955
5. Yang F, Chou D, Schweitzer P, et al. Warfarin in haemodialysis patients with atrial fibrillation: What benefit? Europace. 2010;12:1666-1672
6. Holden RM, Clase CM. Use of warfarin in people with low glomerular filtration rate or on dialysis. Semin Dial. 2009;22:503-511
7. Cozzolino M, Brandenburg V. Warfarin: To use or not to use in chronic kidney disease patients? J Nephrol. 2010;23:648-652
8. Lerner RG, Aronow WS, Sekhri A, et al. Warfarin use and the risk of valvular calcification. J Thromb Haemost. 2009;7:2023-2027
9. Holden RM, Sanfilippo AS, Hopman WM, et al. Warfarin and aortic valve calcification in hemodialysis patients. J Nephrol. 2007;20: 417-422
10. Schurgers LJ, Joosen IA, Laufer EM, et al. Vitamin K-Antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. PLoS One. 2012;7
11. Hristova M, van Beek C, Schurgers LJ, et al. Rapidly progressive severe vascular calcification sparing the kidney allograft following warfarin initiation. Am J Kidney Dis. 2010;56:1158-1162
12. Krishnan S, Chawla N, Ezekowitz MD, et al. Warfarin therapy and systolic hypertension in men with atrial fibrillation. Am J Hypertens. 2005;18(pt 1):1592-1599
13. Demer LL, Tintut Y. Vascular calcification: Pathobiology of a multifaceted disease. Circulation. 2008;117:2938-2948
14. Kapustin AN, Shanahan CM. Calcium regulation of vascular smooth muscle cell-derived matrix vesicles. Trends Cardiovasc Med. 2012;22: 133-137
15. Cannata-Andia JB, Roman-Garcia P, Hruska K. The connections between vascular calcification and bone health. Nephrol Dial Transplant. 2011;26:3429-3436
16. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: The killer of patients with chronic kidney disease. J Am Soc Nephrol. 2009;20: 1453-1464
17. Berkner KL. The vitamin K-dependent carboxylase. Annu Rev Nutr. 2005;25:127-149
18. Berkner KL, Runge KW. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost. 2004;2:2118-2132
19. Soulban G, Labrecque G, Belanger PM. Temporal variation in the effects of warfarin on the vitamin K cycle. Chronobiol Int. 1990;7:403-411
20. Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: The calcification inhibitor in need of vitamin K. Thromb Haemost. 2008;100: 593-603
21. Yao Y, Shahbazian A, Bostrom KI. Proline and gamma-carboxylated glutamate residues in matrix Gla protein are critical for binding of bone morphogenetic protein-4. Circ Res. 2008;102:1065-1074
22. Wallin R, Schurgers L, Wajih N. Effects of the blood coagulation vitamin K as an inhibitor of arterial calcification. Thromb Res. 2008; 122:411-417
23. Herrmann M, Schafer C, Heiss A, et al. Clearance of fetuin-A-containing calciprotein particles is mediated by scavenger receptor-A. Circ Res. 2012;111:575-584
24. Proudfoot D, Shanahan CM. Molecular mechanisms mediating vascular calcification: Role of matrix Gla protein. Nephrology (Carlton). 2006;11: 455-461
25. Schurgers LJ, Spronk HM, Skepper JN, et al. Post-Translational modifications regulate matrix Gla protein function: Importance for inhibition of vascular smooth muscle cell calcification. J Thromb Haemost. 2007;5: 2503-2511
26. Cranenburg EC, Schurgers LJ, Vermeer C. Vitamin K: The coagulation vitamin that became omnipotent. Thromb Haemost. 2007;98:120-125
27. Ing SW, Mohler ER III, Putt ME, et al. Correlates of valvular ossification in patients with aortic valve stenosis. Clin Transl Sci. 2009;2:431-435
28. Koos R, Mahnken AH, Muhlenbruch G, et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol. 2005;96:747-749
29. Koos R, Krueger T, Westenfeld R, et al. Relation of circulating matrix Gla-protein and anticoagulation status in patients with aortic valve calcification. Thromb Haemost. 2009;101:706-713
30. Lomashvili KA, Wang X, Wallin R, et al. Matrix Gla protein metabolism in vascular smooth muscle and role in uremic vascular calcification. J Biol Chem. 2011;286:28715-28722
31. Proudfoot D, Skepper JN, Hegyi L, et al. Apoptosis regulates human vascular calcification in vitro: Evidence for initiation of vascular calcification by apoptotic bodies. Circ Res. 2000;87:1055-1062
32. Zak-Golab A, Okopien B, Chudek J. Witamina K a metabolizm kosci i kalcyfikacja naczyn w przewleklej chorobie nerek [Vitamin K, bone metabolism and vascular calcification in chronic kidney disease]. Przegl Lek. 2011;68:629-632
33. Danziger J. Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin J Am Soc Nephrol. 2008;3:1504-1510
34. Tatarunas V, Lesauskaite V, Veikutiene A, et al. The effect of CYP2-9, VKORC1 and CYP4-2 polymorphism and of clinical factors on warfarin dosage during initiation and long-Term treatment after heart valve surgery. J Thromb Thrombolysis. 2013
35. Hara K, Kobayashi M, Akiyama Y. Comparison of inhibitory effects of warfarin on gamma-carboxylation between bone and liver in rats. J Bone Miner Metab. 2005;23:366-372
36. Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2-9 (CYP2-9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005;106:135-140
37. Wang Y, Zhang W, Zhang Y, et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation. 2006;113:1615-1621
38. Gonzalez-Conejero R, Corral J, Roldan V, et al. The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. J Thromb Haemost. 2007;5: 1701-1706
39. Teichert M, Visser LE, van Schaik RH, et al. Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism and aortic calcification: The Rotterdam Study. Arterioscler Thromb Vasc Biol. 2008; 28:771-776
40. Kohn MH, Price RE, Pelz HJ. A cardiovascular phenotype in warfarinresistant Vkorc1 mutant rats. Artery Res. 2008;2:138-147
41. Cranenburg EC, Vermeer C, Koos R, et al. The circulating inactive form of matrix Gla protein (ucMGP) as a biomarker for cardiovascular calcification. J Vasc Res. 2008;45:427-436
42. Schurgers LJ, Spronk HM, Soute BA, et al. Regression of warfarininduced medial elastocalcinosis by high intake of vitamin K in rats. Blood. 2007;109:2823-2831
43. Kidd PM. Vitamins D and K as pleiotropic nutrients: Clinical importance to the skeletal and cardiovascular systems and preliminary evidence for synergy. Altern Med Rev. 2010;15:199-222
44. Rubin MR, Silverberg SJ. Vascular calcification and osteoporosis - The nature of the nexus. J Clin Endocrinol Metab. 2004;89:4243-4245
45. Fleisch H. Bisphosphonates: Mechanisms of action. Endocr Rev. 1998; 19:80-100
46. Hoshino H, Yamazaki K. Mechanisms of action in bisphosphonates [in Japanese]. Clin Calcium. 2005;15:88-92
47. Neven EG, De Broe ME, D'Haese PC. Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: A new challenge? Kidney Int. 2009;75:580-582
48. Li H, Jia GL, Wang HC, et al. The effect of alendronate on arterial calcification in rat model [in Chinese]. Zhonghua Nei Ke Za Zhi. 2006; 45:489-492
49. Jia P, Li Y, Wang J, et al. The effect of alendronate on the expression of osteopontin and osteoprotegerin in calcified aortic tissue of the rat. Eur J Pharmacol. 2012;682:126-130
50. Saito E, Wachi H, Sato F, et al. Treatment with vitamin k(2) combined with bisphosphonates synergistically inhibits calcification in cultured smooth muscle cells. J Atheroscler Thromb. 2007;14:317-324
51. Palaniswamy C, Selvaraj DR, Selvaraj T, et al. Mechanisms underlying pleiotropic effects of statins. Am J Ther. 2010;17:75-78
52. Mori K, Jono S, Emoto M, et al. Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes. Angiology. 2010;61:86-91
53. Kadoglou NP, Sailer N, Moumtzouoglou A, et al. Aggressive lipidlowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. J Vasc Surg. 2010;51:114-121
54. Trion A, Schutte-Bart C, Bax WH, et al. Modulation of calcification of vascular smooth muscle cells in culture by calcium antagonists, statins, and their combination. Mol Cell Biochem. 2008;308:25-33
55. Li H, Tao HR, Hu T, et al. Atorvastatin reduces calcification in rat arteries and vascular smooth muscle cells. Basic Clin Pharmacol Toxicol. 2010;107:798-802
56. Kizu A, Shioi A, Jono S, et al. Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators. J Cell Biochem. 2004;93:1011-1019
57. Son BK, Kozaki K, Iijima K, et al. Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circ Res. 2006;98:1024-1031
58. Son BK, Akishita M, Iijima K, et al. Mechanism of pi-induced vascular calcification. J Atheroscler Thromb. 2008;15:63-68
59. Hammwohner M, Goette A. Will warfarin soon be passe? New approaches to stroke prevention in atrial fibrillation. J Cardiovasc Pharmacol. 2008;52:18-27
60. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14:1385-1413
61. Fusaro M, Crepaldi G, Maggi S, et al. Bleeding, vertebral fractures and vascular calcifications in patients treated with warfarin: Hope for lower risks with alternative therapies. Curr Vasc Pharmacol. 2011;9:763-769
62. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation *Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747
63. Jimenez D, Yusen RD, Ramacciotti E. Apixaban: An oral direct factor-xa inhibitor. Adv Ther. 2012;29:187-201
64. Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother. 2012;46:e10
65. Bouvet C, Moreau S, Blanchette J, et al. Sequential activation of matrix metalloproteinase 9 and transforming growth factor beta in arterial elastocalcinosis. Arterioscler Thromb Vasc Biol. 2008;28:856-862
66. Kanai S, Uto K, Honda K, et al. Eicosapentaenoic acid reduces warfarininduced arterial calcification in rats. Atherosclerosis. 2011;215:43-51
67. Beazley KE, Deasey S, Lima F, et al. Transglutaminase 2-mediated activation of beta-catenin signaling has a critical role in warfarininduced vascular calcification. Arterioscler Thromb Vasc Biol. 2012; 32:123-130
68. Beazley KE, Banyard D, Lima F, et al. Transglutaminase inhibitors attenuate vascular calcification in a preclinical model. Arterioscler Thromb Vasc Biol. 2012
69. Beazley KE, Eghtesad S, Nurminskaya MV. Quercetin attenuates warfarin- induced vascular calcification in vitro independently from matrix Gla protein. J Biol Chem. 2013;288:2632-2640
70. Cai Y, Xu MJ, Teng X, et al. Intermedin inhibits vascular calcification by increasing the level of matrix gamma-carboxyglutamic acid protein. Cardiovasc Res. 2010;85:864-873
71. Armstrong ZB, Boughner DR, Drangova M, et al. Angiotensin II type 1 receptor blocker inhibits arterial calcification in a pre-clinical model. Cardiovasc Res. 2011;90:165-170
72. Louvet L, Buchel J, Steppan S, et al. Magnesium prevents phosphateinduced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant. 2013;28:869-878